v3.26.3
Consolidated Statements of Operations - USD ($)
12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
REVENUES    
Collaboration and license $ 13,185,031
OPERATING EXPENSES    
Research and development 12,368,873 14,898,494
General and administrative 9,484,446 7,809,345
Gain on sale of Vyleesi (3,130,000)
Gain on purchase commitment (2,117,900)
Total operating expenses 21,853,319 17,459,939
Loss from operations (8,668,288) (17,459,939)
OTHER INCOME (EXPENSE)    
Investment income 297,119 167,665
Foreign currency transaction loss (50)
Interest expense (6,726) (15,025)
Total other income, net 290,393 152,590
NET LOSS $ (8,377,895) $ (17,307,349)
Basic net loss per common share $ (2.96) $ (32.15)
Diluted net loss per common share $ (2.96) $ (32.15)
Weighted average number of common shares outstanding used in computing basic net loss per common share 2,827,233 538,348
Weighted average number of common shares outstanding used in computing diluted net loss per common share 2,827,233 538,348